Table 3.
Influences of methyldopa and its combinations with individual flavonoids on the mRNA expression of selected factors related to inflammatory processes (TNF-α, IL-1β, and IL-6) and cardiovascular diseases (TGF-β, VEGF, PIGF, and HIF-1α) in HUVEC.
| Group | TNF-α | TGF-β | VEGF | PIGF | HIF-1α | IL-1β | IL-6 |
|---|---|---|---|---|---|---|---|
| control | 1.17 ± 0.08 | 1.12 ± 0.06 | 1.12 ± 0.06 | 1.14 ± 0.06 | 1.12 ± 0.03 | 1.01 ± 0.03 | 1.26 ± 0.06 |
| methyldopa | 1.51 ± 0.27 * | 1.54 ± 0.10 * | 1.43 ± 0.01 * | 1.85 ± 0.08 * | 1.35 ± 0.05 * | 1.42 ± 0.05 * | 1.96 ± 0.04 * |
| apigenin | 2.27 ± 0.12 * | 1.50 ± 0.18 * | 1.66 ± 0.16 * | 1.59 ± 0.24 * | 1.90 ± 0.06 * | 1.75 ± 0.05 * | 1.55 ± 0.04 * |
| Methyldopa + apigenin | 1.37 ± 0.03 | 1.27 ± 0.05 # | 1.36 ± 0.18 | 1.43 ± 0.09 *,# | 1.16 ± 0.02 # | 1.60 ± 0.10 * | 1.15 ± 0.07 # |
| baicalein | 1.64 ± 0.04 * | 1.48 ± 0.02 * | 1.44 ± 0.03 * | 1.56 ± 0.11 * | 1.60 ± 0.05 * | 1.57 ± 0.07 * | 1.44 ± 0.03 * |
| Methyldopa + baicalein | 1.40 ± 0.09 | 1.21 ± 0.02 # | 1.34 ± 0.14 | 1.43 ± 0.02 *,# | 1.15 ± 0.03 # | 1.59 ± 0.01 * | 1.10 ± 0.04 *,# |
| chrysin | 1.52 ± 0.01 * | 1.57 ± 0.07 * | 1.40 ± 0.01 * | 1.50 ± 0.07 * | 1.50 ± 0.06 * | 1.36 ± 0.07 * | 1.41 ± 0.01 * |
| Methyldopa + chrysin | 1.16 ± 0.05 # | 1.16 ± 0.08 # | 1.36 ± 0.10 | 1.36 ± 0.03 *,# | 1.12 ± 0.01 # | 1.70 ± 0.05 *,# | 1.08 ± 0.01 *,# |
| quercetin | 1.63 ± 0.03 * | 1.41 ± 0.04 * | 1.43 ± 0.08 * | 1.40 ± 0.05 | 1.52 ± 0.04 * | 1.32 ± 0.04 * | 1.55 ± 0.04 * |
| Methyldopa + quercetin | 1.15 ± 0.15 # | 1.17 ± 0.04 # | 1.30 ± 0.04 | 1.30 ± 0.07 # | 1.02 ± 0.01 # | 1.52 ± 0.06 * | 1.02 ± 0.01 *,# |
| scutellarin | 1.63 ± 0.04 * | 1.70 ± 0.10 * | 1.69 ± 0.04 * | 1.69 ± 0.10 * | 1.66 ± 0.06 * | 1.44 ± 0.05 * | 1.40 ± 0.04 * |
| Methyldopa + scutellarin | 1.14 ± 0.03 # | 1.23 ± 0.14 # | 1.30 ± 0.10 | 1.38 ± 0.07 # | 1.14 ± 0.04 # | 1.35 ± 0.14 * | 1.12 ± 0.02 *,# |
Values are presented as ratios against mRNA GAPDH expression. Mean ± SD. *—vs. control, p < 0.05. #—vs. methyldopa, p < 0.05.